This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage …

Advanced Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03191149

Phase 2

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has …

Stage III Lung Cancer AJCC v8Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Cancer AJCC v8+4 more

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT04892953